Wordt geladen...
The BTK Inhibitor ARQ 531 Targets Ibrutinib Resistant CLL and Richter’s Transformation
Targeted inhibition of Bruton’s tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has improved outcomes for patients with hematologic malignancies, including chronic lymphocytic leukemia (CLL). Here we describe preclinical investigations of ARQ 531, a potent, reversible inhibitor of BT...
Bewaard in:
| Gepubliceerd in: | Cancer Discov |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6261467/ https://ncbi.nlm.nih.gov/pubmed/30093506 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-17-1409 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|